Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 121, Issue 6, Pages 2149-2152Publisher
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI58025
Keywords
-
Categories
Funding
- NIDDK NIH HHS [R01 DK041274, 5R01DK067286, 2R01DK041274, R01 DK067286] Funding Source: Medline
Ask authors/readers for more resources
Preclinical studies with probiotics continue to unravel mechanisms of cytoprotection and suggest that approaches utilizing microbial products as therapeutics in acute and chronic gastrointestinal disorders could be effective. However, clinical trials using these bacteria have thus far been inconsistent. In this issue of the JCI, Yan et al. describe a novel mechanism of cytoprotection by p40, a soluble product of Lactobacillus rhamnosus GG, mediated via EGER. The efficacy of p40 in three models of chemically induced colitis indicates tremendous therapeutic potential, though this finding will need to be verified in human patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available